Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

In the Q2W GZR18 dose groups, participants experienced ... Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), ...

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

Immunocompromised people and those who are age 65 or older should get a second dose of the 2024-2025 COVID-19 vaccine, according to the latest recommendations from the Centers for Disease Control ...

Federal officials have celebrated a striking drop in drug overdoses across the country. But state-level data shows that Black people are suffering significantly worse outcomes than white people.

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) officially recommended.

Earlier this year, Eli Lilly reported temporary shortages of Humalog and insulin lispro in 10-milliliter ... are approved to treat weight loss. Drug companies have invested hundreds of millions ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs Humalog and insulin lispro were in short supply. Novo Nordisk ...

Death is imminent," Wright said. Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi.